ZELLUNA IMMUNOTHERAPY AS

0379 OSLO

Finances

Share Ownership

Return on Equity

−36,8 %

Current Ratio

14,37

Debt-to-Equity Ratio

Key figures (NOK)	2022	2021	2020	2019
Revenue	13 300 000	13 125 000	12 421 000	11 373 000
Net Income	−49 072 000	−35 317 000	−34 264 000	−62 449 000
Total Assets	142 808 000	84 105 000	57 471 000	49 120 000
Total Equity	133 331 000	76 959 000	50 954 000	36 577 000

Income (NOK)	2022	2021	2020	2019
Revenue	13 300 000	13 125 000	12 421 000	11 373 000
Expenditure	65 453 000	47 784 000	45 989 000	73 576 000
Operating Profit	−52 153 000	−34 659 000	−33 568 000	−62 203 000
Financial Income	3 537 000	1 783 000	284 000	595 000
Financial Costs	456 000	2 442 000	980 000	840 000
Financial Balance	3 081 000	−659 000	−696 000	−245 000
Earnings Before Tax	−49 072 000	−35 317 000	−34 264 000	−62 449 000
Tax	0	0	0	0
Net Income	−49 072 000	−35 317 000	−34 264 000	−62 449 000

Balance (NOK)	2022	2021	2020	2019
Total Fixed Assets	6 597 000	4 524 000	1 473 000	2 221 000
Total Current Assets	136 211 000	79 581 000	55 998 000	46 899 000
Total Assets	142 808 000	84 105 000	57 471 000	49 120 000
Total Retained Equity	0	0	0	0
Total Equity	133 331 000	76 959 000	50 954 000	36 577 000
Total Long-Term Debt	0	0	0	0
Total Current Debt	9 478 000	7 146 000	6 517 000	12 542 000
Total Equity and Debt	142 808 000	84 105 000	57 471 000	49 120 000

Cash flow (NOK)	2022	2021	2020	2019
Sales Income	0	0	167 000	0
Other Income	13 300 000	13 125 000	12 254 000	11 373 000
Revenue	13 300 000	13 125 000	12 421 000	11 373 000
Cost of Goods Sold	0	0	0	0
Salary Costs	27 438 000	21 040 000	19 831 000	20 109 000
Depreciation	1 309 000	695 000	254 000	212 000
Impairment	0	0	0	0
Expenditure	65 453 000	47 784 000	45 989 000	73 576 000
Operating Profit	−52 153 000	−34 659 000	−33 568 000	−62 203 000
Financial Income	3 537 000	1 783 000	284 000	595 000
Financial Costs	456 000	2 442 000	980 000	840 000
Financial Balance	3 081 000	−659 000	−696 000	−245 000
Dividends	0	0	0	0
Net Income	−49 072 000	−35 317 000	−34 264 000	−62 449 000

Balance details (NOK)	2022	2021	2020	2019
Goodwill	0	0	0	0
Total Intangible Assets	0	1 000	12 000	22 000
Real Eastate	0	0	0	0
Machinery and Plant Facilities	5 768 000	3 762 000	777 000	1 416 000
Fixtures	305 000	245 000	168 000	204 000
Total Tangible Assets	6 073 000	4 006 000	945 000	1 620 000
Total Fiancial Fixed Assets	525 000	517 000	516 000	579 000
Total Fixed Assets	6 597 000	4 524 000	1 473 000	2 221 000
Stock	0	0	0	0
Total Investments	0	0	0	0
Cash, Bank	125 491 000	68 657 000	49 603 000	36 216 000
Total Current Assets	136 211 000	79 581 000	55 998 000	46 899 000
Total Assets	142 808 000	84 105 000	57 471 000	49 120 000
Total Equity	133 331 000	76 959 000	50 954 000	36 577 000
Short-Term Group Debt	0	0	0	0
Total Long-Term Debt	0	0	0	0
Creditors	2 953 000	1 472 000	1 979 000	5 363 000
Unpaid Taxes	1 335 000	979 000	791 000	1 023 000
Dividends	0	0	0	0
Other Current Debt	5 190 000	4 694 000	3 747 000	6 157 000
Total Current Debt	9 478 000	7 146 000	6 517 000	12 542 000
Total Equity and Debt	142 808 000	84 105 000	57 471 000	49 120 000

Financial indicators	2022	2021	2020	2019
Return on Equity	−36,8 %	−45,89 %	−67,24 %	−170,73 %
Debt-to-Equity Ratio	0	0	0	0
Operating Profit Margin	−392,13 %	−264,07 %	−270,25 %	−546,94 %
Current Ratio	14,37	11,14	8,59	3,74
Quick Ratio	14,37	11,14	8,59	3,74
Equity Ratio	0,93	0,92	0,89	0,74
Gross Profit Margin	100 %	100 %	100 %	100 %